This page allows you to read information about people engaged in research at CAMH. You can search for researchers using the
name or keyword search engine below.
Dr. Bernard Le Foll
Translational Addiction Research Laboratory Centre for Addiction and Mental Health 33 Russell Street Toronto, Ontario M5S 2S1 (416) 535-8501 ext. 4772 bernard_lefoll@camh.net
Dr. Bernard Le Foll is a Clinician Scientist and Head of the Translational Addiction Research Laboratory in the Neuroscience Department. He is an Associate Professor with the Departments of Family and Community Medicine, Pharmacology and Psychiatry at the University of Toronto.
Dr. Le Foll specializes in diverse approaches to explore the neurobiological factors underlying addictive behaviours. The research is aimed at linking discoveries in basic science to clinical applications, to improve the treatment and understanding of smoking dependence. Dr. Le Foll is examining animal models of nicotine addiction to determine the usefulness of candidate receptors to treat tobacco dependence. He is also collaborating with several scientists, inside and outside CAMH including the National Institute on Drug Abuse, on projects aimed at understanding novel treatment approach for smokers; factors that underlie tobacco dependence; the role of polymorphisms of the dopamine DRD3 gene in vulnerability to tobacco dependence; changes in dopamine receptor expression; and function in the brain of smokers.
Publications
Le Foll B, Goldberg SR, Sokoloff. Dopamine D3 receptor and drug dependence: effect on reward or beyond? Neuropharmacol. 2005;49: 525-41.
Le Foll B, Goldberg SR. Control of the reinforcing effects of nicotine by associated environmental stimuli in animals and humans. Trends in Pharmacol. Sci. 2005;26: 287-93.
Le Foll B, Melihan-Cheinin P, Rostoker G, Lagrue G. for the working group of AFSSAPS. Smoking cessation guidelines: recommendations of the French Health Products Safety Agency. Eur. Psychiat. 2005;20: 431-41.
Le Foll B, Diaz J, Sokoloff P. A single cocaine exposure increases BDNF and D3 receptor expressions: possible implications for drug conditioning. Neuroreport. 2005;16: 175-178.
Le Foll B, Goldberg SR. Cannabinoid CB1 antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther. 2005;312: 875-883.
Le Foll B, Sokoloff P, Stark H, Goldberg SR. Dopamine D3 receptor ligands block nicotine-induced conditioned place preferences through a mechanism that does not involve discriminative-stimulus or antidepressant-like effects. Neuropsychopharmacology. 2005;30: 720-730.
Le Foll B, Goldberg SR. Nicotine induces conditioned place preferences over a large range of doses in rats. Psychopharmacology (Berl). 2005;178: 481-492.
Le Foll B, Diaz J, Sokoloff P. Neuroadaptations to hyperdopaminergia in dopamine D3 receptor deficient mice, Life Sciences. 2005;76:1281-1296.
Centre for Addiction
